WO2000054575A2 - Infant formulas and other food products containing phospholipids - Google Patents

Infant formulas and other food products containing phospholipids Download PDF

Info

Publication number
WO2000054575A2
WO2000054575A2 PCT/US2000/006755 US0006755W WO0054575A2 WO 2000054575 A2 WO2000054575 A2 WO 2000054575A2 US 0006755 W US0006755 W US 0006755W WO 0054575 A2 WO0054575 A2 WO 0054575A2
Authority
WO
WIPO (PCT)
Prior art keywords
phospholipids
food product
derived
fatty acid
acid residues
Prior art date
Application number
PCT/US2000/006755
Other languages
French (fr)
Other versions
WO2000054575A3 (en
Inventor
David J. Kyle
Claus C. Becker
Original Assignee
Martek Biosciences Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Martek Biosciences Corporation filed Critical Martek Biosciences Corporation
Priority to AU38845/00A priority Critical patent/AU3884500A/en
Publication of WO2000054575A2 publication Critical patent/WO2000054575A2/en
Publication of WO2000054575A3 publication Critical patent/WO2000054575A3/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L3/00Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs
    • A23L3/34Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs by treatment with chemicals
    • A23L3/3454Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs by treatment with chemicals in the form of liquids or solids
    • A23L3/3463Organic compounds; Microorganisms; Enzymes
    • A23L3/3553Organic compounds containing phosphorus
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23DEDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS, COOKING OILS
    • A23D9/00Other edible oils or fats, e.g. shortenings, cooking oils
    • A23D9/007Other edible oils or fats, e.g. shortenings, cooking oils characterised by ingredients other than fatty acid triglycerides
    • A23D9/013Other fatty acid esters, e.g. phosphatides
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23JPROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
    • A23J7/00Phosphatide compositions for foodstuffs, e.g. lecithin
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12Fatty acids or derivatives thereof

Definitions

  • This invention is directed to the formulation of food products containing highly unsaturated fatty acids, and to processes for stabilizing such products.
  • HUFA highly unsaturated fatty acids
  • this invention provides a method for preparing a food product containing triglyceride oil having highly unsaturated fatty acid residues in which oxidation of the highly unsaturated fatty acid residues is minimized during the preparation by blending phospholipids with the triglyceride oil in an amount effective to reduce oxidation of the highly unsaturated fatty acid residues during subsequent processing steps and during storage.
  • the phospholipids may be derived from vegetable sources, milk fat, milk processing waste products, microbial sources, such as yeast brewing waste products, and like sources.
  • the phospholipids are vegetable-derived.
  • the phospholipids are not derived from animal sources other than milk sources.
  • this invention provides food products containing triglyceride oil having highly unsaturated fatty acid residues, where the highly unsaturated fatty acid (HUFA) residues are partially stabilized against oxidation during processing and storage by phospholipids which are present in the food product in an amount effective to reduce oxidative damage to the highly unsaturated fatty acid residues.
  • the phospholipids are obtained from vegetable sources; but they may also be obtained from milk fat, milk processing waste products, and like sources.
  • Food products according to this invention include infant formula and baby food.
  • Food products according to this invention also include nutritional supplements, such as HUFA-containing oil and /or HUFA-containing biomass formulated for consumption in, e.g., capsules, tablets, emulsions (including water in oil emulsions and oil in water emulsions), or sustained release capsules.
  • nutritional supplements such as HUFA-containing oil and /or HUFA-containing biomass formulated for consumption in, e.g., capsules, tablets, emulsions (including water in oil emulsions and oil in water emulsions), or sustained release capsules.
  • Other non- exhaustive examples of food products according to this invention include butters, spreads, cooking oils, salad dressings, and chocolate, in which part of the oil has been replaced by a HUFA-containing oil.
  • the HUFA residues are partially stabilized against oxidation by phospholipids that are present in the food product in an amount effective to reduce oxidative damage to the HUFA residues during processing and storage.
  • Suitable methods for the preparation of these food products are well-known in the art.
  • Figure 1 Graphic representation if the effect of lecithin on induction time of an oil blend of ARASCO® and DHASCO®.
  • Figure 2 Graphic representation if the effect of lecithin on induction time of an oil blend of DHASCO®.
  • the present invention involves the addition of a quantity of phospholipids to the fat blend of an infant formula or other food product at levels of up to 30% by weight of the fat blend, which results in the stabilization, especially the oxidative or chemical stabilization, of that fat blend to processing steps such as, but not limited to, spray drying, retort sterilization, pasteurization, ultra high temperature (UHT) processing, or extrusion and in the stabilization of that fat blend during storage.
  • These phospholipids are preferably sourced from vegetable material including, but not limited to, soy, corn, palm, canola, rice, flax, coconut, and combinations thereof, and are usually obtained as a byproduct of the process of refining the vegetable oil.
  • These phospholipids may also be obtained from milk fats, milk processing waste products, microbial sources, such as yeast brewing waste products, and like sources.
  • the phospholipids are not derived from animal sources other than milk sources.
  • the term "non-animal” will not encompass milk or milk products or products derived from milk or milk products.
  • These phospholipids may be comprised of any of phosphatidyl choline (PC), phosphatidyl serine (PS), phosphatidyl ethanolamine (PE) and/or phosphatidyl inositol (PI), or a combination thereof.
  • PC phosphatidyl choline
  • PS phosphatidyl serine
  • PE phosphatidyl ethanolamine
  • PI phosphatidyl inositol
  • these materials are distinguished from animal phospholipids in that they are less likely to contain certain fatty acids such as docosahexaenoic acid (DHA) or arachidonic acid (ARA).
  • DHA docosahexaenoic acid
  • ARA arachidonic acid
  • phospholipids particularly vegetable phospholipids
  • LCPUFAs long chain polyunsaturated fatty acids
  • DHA and ARA long chain polyunsaturated fatty acids
  • the addition of phospholipids according to the present invention will further stabilize the final product to provide a longer shelf life.
  • lecithin (Yelkin TS from ADM (Archer Daniels Midland Company, Decatur, IL 62526); Yelkin contains approximately 63% phospholipids) at concentrations of from 0.4 to 8.0% to a blend of DHA-rich oil (e.g., DHASCO® brand (Martek Biosciences Corp., Columbia, MD, USA 21045) triglyceride oil from Crypthecodinium cohnii) and ARA-rich oil (e.g. ARASCO® brand triglyceride oil from Mortierella alpina) dramatically retarded oxidation of the oil. Addition of lecithin extended the induction time in a dose-dependent manner.
  • DHA-rich oil e.g., DHASCO® brand (Martek Biosciences Corp., Columbia, MD, USA 21045) triglyceride oil from Crypthecodinium cohnii
  • ARA-rich oil e.g. ARASCO® brand triglyceride
  • Induction time is a measurement of oxidative stability: the longer the induction time for a given sample, the greater its oxidative stability.
  • the induction time determined using Rancimat® was increased by approximately eight hours.
  • the induction time was increased by ten to eleven hours. See Example 1, Table 1 and Figure 1, below.
  • This invention provides for the addition of a stabilizing agent of vegetable or microbial origin to an infant formula or other dietetic products.
  • This agent is not of animal origin and products according to this invention may therefore be fully vegetarian or vegan products.
  • it provides a source of phospholipids in large quantity to improve the nutritional quality of the infant formula.
  • PS, PE, and PC are known to be important for brain development and are found in human milk.
  • animal phospholipids which contain DHA and ARA are being added to infant formulas as sources of DHA and/or ARA, but these sources are highly sensitive to oxidation.
  • DHA and ARA e.g., egg yolk, placental lipids; see, e.g., Clandinin and Milupa patents; placental lipids patent of Bio-extraction
  • the present invention solves the problem of oxidation by adding large amounts of plant-, milk, and/or microbial-derived phospholipid which is not as sensitive to oxidation and which also imparts an unexpected oxidative stability to fats which contain high levels of DHA and ARA.
  • the plant-, milk, and or microbial-derived phospholipids may also be added to formulas where animal phospholipids such as egg yolk are already added.
  • animal phospholipids such as egg yolk are already added.
  • Phospholipids derived from vegetable sources, milk fats, milk processing waste products, microbial sources, such as yeast brewing waste products, and like sources are not as sensitive to oxidation as other animal phospholipids that contain DHA and ARA and impart an unexpected oxidative stability to fats which contain high levels of DHA and ARA.
  • Plant-derived phospholipids, milk-derived, and microbial-derived phospholipids may be blended together in any suitable combination in embodiments according to the present invention.
  • the prior art suggested that egg phospholipids or brain phospholipids should be added to infant formulas to provide sources of DHA and ARA.
  • Providing a source of phospholipids which specifically does not contain DHA or ARA is contrary to the aforementioned inventions. Indeed, the previous patents teach away from the use of plant-derived or milk-derived phospholipids because of the deficiency of DHA and ARA in the plant phospholipids and non-human milk phospholipids. Similarly, the previous patents teach away from the use of microbial-derived phospholipids that do not contain ARA and or DHA. Rather, the phospholipids are added to match more closely the fat blend of human milk with respect to overall complex lipids (i.e., phospholipid) content.
  • Lecithin (PC) at a level of from 200-2000 ppm in combination with vitamin E and ascorbyl palmitate has been shown by Hoffrnan-La Roche (see product Ronoxan, an antioxidant) to have an improvement in antioxidant capability compared to each of the individual components alone.
  • the benefit provided by the levels of phospholipids taught by the present invention greatly exceed the benefit provided by Ronoxan.
  • the benefits of adding concentrations of phospholipids higher than 2000 ppm could not be predicted from the benefits of adding phospholipids at 2000 ppm or less.
  • Example 2 which compares induction times for DHASCO® plus 250 ppm ascorbyl palmitate and 250 ppm mixed tocopherols supplemented with the phospholipids of the present invention vs. DHASCO® supplemented only with the phospholipids of the present invention, a given amount of phospholipids is effective to substantially increase the stability of the oil for DHASCO® without additional antioxidants as well as for DHASCO® with additional antioxidants.
  • the present invention provides for the addition of vegetable-derived, milk- derived, and/or microbial-derived phospholipids to the fat blend or food fat of infant formulas and other food products at levels up to 30% by weight of the fat blend, formula fat, or other food fat.
  • the phospholipids are added at levels of from 0.4% to 20% (preferably 0.5% to 20%, more preferably 1% to 16%, and even more preferably 4% to 16%) of the fat blend.
  • the phospholipids are added in an amount effective to substantially increase the stability, particularly the oxidative stability, of the fat blend.
  • An amount effective to substantially increase the stability is an amount effective to increase the induction time by 50% above the induction time of the same fat blend to which the phospholipids of this invention have not been added.
  • the effective amount of phospholipids will increase the induction time by a factor of 2 to 5 times greater than the induction time of the same fat blend to which the phospholipids of this invention have not been added.
  • the amount of the phospholipids of the present invention which will constitute an effective amount may vary with the components of the fat blend the stability of which is desired to be increased.
  • the optimal amount of phospholipids to add to a particular fat blend may be determined through routine optimization studies. As an example, Example 1 presents an experiment wherein the stabilizing effect of the phospholipids of the present invention on a blend of DHASCO® and ARASCO® is examined. In contrast, Example 2 an experiment wherein the stabilizing effect of the phospholipids of the present invention on DHASCO® is examined. It can be seen from the results that optimum amounts of phospholipids vary slightly between the blend versus the DHASCO® alone.
  • the phospholipids of this invention may be added in addition to other stabilizing agents such as, but not limited to, tocopherols, ascorbic acid and its derivatives, such as ascorbyl palmitate, and BHT.
  • stabilizing agents will be referred to as “additional stabilizing agents” or “additional antioxidants.”
  • the high levels of phospholipids conceived in this invention provide unexpected chemical (e.g., oxidative) stability to the fat blend used in the formula or food by generating an emulsion which is beneficial to the spray drying process.
  • the levels of phospholipids added according to the present invention are much higher than the upper limits previously though to be useful, and it is an unexpected result that the increasing levels of phospholipid addition provide increasing levels of stability.
  • the phospholipids of the present invention provide their stabilizing effect in the absence of any other antioxidants or stabilizers. However, such other antioxidants and/or stabilizers may optionally be added to oil blends in combination with the phospholipids of the present invention.
  • phospholipids should impart an additional nutritive benefit to the infant formula as these components are important in the metabolism and physiology of the growing infant.
  • the addition of the phospholipids have imparted a previously unexpected stability on certain oils which are rich in ARA and /or DHA, such as, but not limited to, ARA-containing oil from Mortierella alpina (see U.S. Patent No. 5,658,767 to Kyle), DHA-containing oil from Crypthecodinium cohnii (see U.S. Patent No. 5,492,938 to Kyle et al.; U.S. Patent No. 5,407,957 to Kyle, et al.; U.S. Patent No. 5,397,591 to Kyle et al.), and DHA-containing oil from Thraustochytrium species (see U.S. Patent No. 5,130,242 to Barclay).
  • ARA-containing oil from Mortierella alpina see U.S. Patent No. 5,658,767 to Kyle
  • DHASCO® a DHA- rich oil from Crypthecodinium cohnii
  • ARASCO® an ARA-rich triglyceride oil from Mortierella alpina
  • Lots of Formulaid (an oil containing ARASCO® and DHASCO®) were blended to yield an oil containing DHA and ARA in a ratio of 1:1.5. Specifically, lots F01723-DS-7 (DHA: ARA of 1:1) and F01723-DS-1 (DHA: ARA of 1:2) were blended in a 1 : 1 ratio.
  • Bleached lecithin (Yelkin TS from ADM, lot #PG386) was added to the oil blend.
  • the lecithin contained approximately 63% phospholipids (as acetone insoluble matter) and soybean oil.
  • ADM states that the lecithin naturally contains approximately 1000 ppm tocopherol, but no added antioxidants.
  • the lecithin was added to the oil blend at concentrations of 0.4%, 0.8%, 4.0%, and 8.0% and mixed well.
  • Oxidative stability may also be assessed using the active oxygen method (AOM), which is well-known in the art.
  • AOM active oxygen method
  • DHASCO® a DHA-rich oil from Crypthecodinium cohnii supplemented with 250 ppm ascorbyl palmitate and 250 ppm mixed tocopherols was investigated and compared to the antioxidant effectiveness of lecithin in DHASCO® with neither ascorbyl palmitate nor tocopherols added ("DHASCO® w/o antioxidant").
  • Bleached lecithin (Yelkin TS from ADM, lot #PG386) was added to the DHASCO®.
  • the lecithin contained approximately 63% phospholipids (as acetone insoluble matter) and soybean oil.
  • ADM states that the lecithin naturally contains approximately 1000 ppm tocopherol, but no added antioxidants.
  • the lecithin was added to the DHASCO® at concentrations of 1.0%, 2.0%, 4.0%, and 8.0% or 16.0% and mixed well.
  • Oxidative stability may also be assessed using the active oxygen method (AOM), which is well-known in the art.
  • AOM active oxygen method

Abstract

A food product containing mixed glycerides, including polyunsaturated fatty acid residues, highly unsaturated fatty acid residues, or a combination thereof, is stabilized by the addition of phospholipids. The addition of phospholipids to fat blends has been found to have an unexpected stabilizing effect on the fats contained in the blend. The phospholipids are preferably derived from vegetables, milk, microbes, or a combination thereof.

Description

INFANT FORMULAS AND OTHER FOOD PRODUCTS CONTAINING PHOSPHOLIPIDS
BACKGROUND OF THE INVENTION Field of the Invention:
This invention is directed to the formulation of food products containing highly unsaturated fatty acids, and to processes for stabilizing such products.
Review of Related Art:
The importance of highly unsaturated fatty acids (HUFA) in the diet of humans, and particularly infants, is now well established (see e.g., WO 96/40106). Typical dietary sources of HUFA are organ meats, fish, eggs and human breast milk. However, present day diets are frequently deficient in HUFA, resulting in a need to supplement the diet with a source of HUFA. Sources of HUFA supplements include egg yolk phospholipids, and triglyceride oils extracted from fish and marine microorganisms. Use of egg yolk phospholipids and/or marine triglyceride oils to supply HUFA in infant formula is taught in U.S. Patent No. 4, 670,285 by Clandinin, et al., and WO 96/10922 by Milupa. Use of microbial triglyceride oils to supply HUFA in infant formula is taught in U.S. Patent Nos. 5,374,657, 5,397,591 and 5,550,156 by Kyle, et al. Another source to supply HUFA in infant formula is a lipid extract from human placenta, taught in European Patent No. 0 140 805 to Bio- Extraction.
The Clandinin and Milupa patents (use of egg yolk phospholipids) and Bio- extraction (use of placental phospholipids) all describe animal sources of phospholipids that are used in infant formulas because of their DHA and ARA contents. Phospholipids (gums) are already added to foods (including infant formula), and these phospholipids are generally vegetable-derived phospholipids because they are relatively inexpensive. However, the levels of phospholipid added are generally less than 0.5% by weight of the fat blend, especially in infant formulas, and they are added to improve the physical properties of the product. For example, phospholipids may be added as emulsifiers or wetting agents. Because of their degree of unsaturation, HUFA are prone to oxidative degradation. Preserving the double bonds of the HUFA through processing and storage is a critical issue in the preparation and distribution of infant formula, baby food and other nutritional supplements containing such materials. European Patent No. 0 404 058 to Milupa describes the addition of alpha-tocopherol and or ascorbyl- palmitate as antioxidants during preparation of HUFA-containing mixtures to reduce oxidative degradation. The HUFA-containing materials are added to a mixture containing antioxidants in amounts to give final concentration of from 150-300 ppm, and the mixture typically contains mono- and diglyceride emulsifiers. U.S. Patent No. 5,855,944 by Koschinski, et al., describes a process for stabilizing HUFA- containing marine oils by treating the oils with silica, steam deodorizing the oil, and then adding to the oil a mixture of food-grade lecithin, alpha-tocopherol, and ascorbyl-palmitate in a total amount of 1000-4000 ppm of the mixture.
However, there remains a need for a inexpensive, effective method for chemically stabilizing products which contain PUFAs and/or HUFAs.
SUMMARY OF THE INVENTION
In one embodiment, this invention provides a method for preparing a food product containing triglyceride oil having highly unsaturated fatty acid residues in which oxidation of the highly unsaturated fatty acid residues is minimized during the preparation by blending phospholipids with the triglyceride oil in an amount effective to reduce oxidation of the highly unsaturated fatty acid residues during subsequent processing steps and during storage. The phospholipids may be derived from vegetable sources, milk fat, milk processing waste products, microbial sources, such as yeast brewing waste products, and like sources. Preferably, the phospholipids are vegetable-derived. Preferably, the phospholipids are not derived from animal sources other than milk sources. In another embodiment, this invention provides food products containing triglyceride oil having highly unsaturated fatty acid residues, where the highly unsaturated fatty acid (HUFA) residues are partially stabilized against oxidation during processing and storage by phospholipids which are present in the food product in an amount effective to reduce oxidative damage to the highly unsaturated fatty acid residues. Preferably, the phospholipids are obtained from vegetable sources; but they may also be obtained from milk fat, milk processing waste products, and like sources.
Food products according to this invention include infant formula and baby food. Food products according to this invention also include nutritional supplements, such as HUFA-containing oil and /or HUFA-containing biomass formulated for consumption in, e.g., capsules, tablets, emulsions (including water in oil emulsions and oil in water emulsions), or sustained release capsules. Other non- exhaustive examples of food products according to this invention include butters, spreads, cooking oils, salad dressings, and chocolate, in which part of the oil has been replaced by a HUFA-containing oil. In each of these food products, the HUFA residues are partially stabilized against oxidation by phospholipids that are present in the food product in an amount effective to reduce oxidative damage to the HUFA residues during processing and storage. Suitable methods for the preparation of these food products are well-known in the art.
BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1. Graphic representation if the effect of lecithin on induction time of an oil blend of ARASCO® and DHASCO®.
Figure 2. Graphic representation if the effect of lecithin on induction time of an oil blend of DHASCO®.
DETAILED DESCRIPTION OF THE EMBODIMENTS
The present invention involves the addition of a quantity of phospholipids to the fat blend of an infant formula or other food product at levels of up to 30% by weight of the fat blend, which results in the stabilization, especially the oxidative or chemical stabilization, of that fat blend to processing steps such as, but not limited to, spray drying, retort sterilization, pasteurization, ultra high temperature (UHT) processing, or extrusion and in the stabilization of that fat blend during storage. These phospholipids are preferably sourced from vegetable material including, but not limited to, soy, corn, palm, canola, rice, flax, coconut, and combinations thereof, and are usually obtained as a byproduct of the process of refining the vegetable oil. These phospholipids may also be obtained from milk fats, milk processing waste products, microbial sources, such as yeast brewing waste products, and like sources. Preferably, the phospholipids are not derived from animal sources other than milk sources. For the purposes of this invention, the term "non-animal" will not encompass milk or milk products or products derived from milk or milk products. These phospholipids may be comprised of any of phosphatidyl choline (PC), phosphatidyl serine (PS), phosphatidyl ethanolamine (PE) and/or phosphatidyl inositol (PI), or a combination thereof. Unlike egg yolk phospholipids and placental phospholipids, for example, these materials are distinguished from animal phospholipids in that they are less likely to contain certain fatty acids such as docosahexaenoic acid (DHA) or arachidonic acid (ARA).
The inventors have discovered that addition of phospholipids, particularly vegetable phospholipids, has an effect of stabilizing a fat blend containing HUFAs and/or long chain polyunsaturated fatty acids (LCPUFAs), such as DHA and ARA, in an emulsion which is protected from damage, especially oxidative damage, during harsh processing steps such as, but not limited to, spray drying. Furthermore, the addition of phospholipids according to the present invention will further stabilize the final product to provide a longer shelf life. In particular, laboratory data demonstrates that the addition of soy lecithin (primarily PC) at levels of 0.1% and 0.5% tremendously reduced the oxidizability of an oil rich in ARA (e.g., ARASCO® brand (Martek Biosciences Corp., Columbia, MD, USA 21045) triglyceride oil from Mortierella alpina). This stabilization, unexpectedly appeared to be about 4-fold better than the addition of Vitamin E at levels of 50 or 150 ppm. Phospholipids from milk and microbial sources also have this effect.
Similarly, laboratory data demonstrates that the addition of lecithin (Yelkin TS from ADM (Archer Daniels Midland Company, Decatur, IL 62526); Yelkin contains approximately 63% phospholipids) at concentrations of from 0.4 to 8.0% to a blend of DHA-rich oil (e.g., DHASCO® brand (Martek Biosciences Corp., Columbia, MD, USA 21045) triglyceride oil from Crypthecodinium cohnii) and ARA-rich oil (e.g. ARASCO® brand triglyceride oil from Mortierella alpina) dramatically retarded oxidation of the oil. Addition of lecithin extended the induction time in a dose-dependent manner. Induction time is a measurement of oxidative stability: the longer the induction time for a given sample, the greater its oxidative stability. Surprisingly, for every one percent lecithin added (after the first 0.4%), the induction time determined using Rancimat® (Metrohm Ltd., CH-9101, Herisau, Switzerland) was increased by approximately eight hours. Expressed in phospholipids, for every one percent of phospholipid added, the induction time was increased by ten to eleven hours. See Example 1, Table 1 and Figure 1, below.
This invention provides for the addition of a stabilizing agent of vegetable or microbial origin to an infant formula or other dietetic products. This agent is not of animal origin and products according to this invention may therefore be fully vegetarian or vegan products. Furthermore, it provides a source of phospholipids in large quantity to improve the nutritional quality of the infant formula. Of particular importance is the provision of PS, PE, and PC to the formula as these nutrients are known to be important for brain development and are found in human milk.
At present, animal phospholipids which contain DHA and ARA (e.g., egg yolk, placental lipids; see, e.g., Clandinin and Milupa patents; placental lipids patent of Bio-extraction) are being added to infant formulas as sources of DHA and/or ARA, but these sources are highly sensitive to oxidation. The present invention solves the problem of oxidation by adding large amounts of plant-, milk, and/or microbial-derived phospholipid which is not as sensitive to oxidation and which also imparts an unexpected oxidative stability to fats which contain high levels of DHA and ARA. The plant-, milk, and or microbial-derived phospholipids may also be added to formulas where animal phospholipids such as egg yolk are already added. Phospholipids derived from vegetable sources, milk fats, milk processing waste products, microbial sources, such as yeast brewing waste products, and like sources are not as sensitive to oxidation as other animal phospholipids that contain DHA and ARA and impart an unexpected oxidative stability to fats which contain high levels of DHA and ARA. Plant-derived phospholipids, milk-derived, and microbial-derived phospholipids may be blended together in any suitable combination in embodiments according to the present invention. The prior art suggested that egg phospholipids or brain phospholipids should be added to infant formulas to provide sources of DHA and ARA. Providing a source of phospholipids which specifically does not contain DHA or ARA is contrary to the aforementioned inventions. Indeed, the previous patents teach away from the use of plant-derived or milk-derived phospholipids because of the deficiency of DHA and ARA in the plant phospholipids and non-human milk phospholipids. Similarly, the previous patents teach away from the use of microbial-derived phospholipids that do not contain ARA and or DHA. Rather, the phospholipids are added to match more closely the fat blend of human milk with respect to overall complex lipids (i.e., phospholipid) content.
Lecithin (PC) at a level of from 200-2000 ppm in combination with vitamin E and ascorbyl palmitate, has been shown by Hoffrnan-La Roche (see product Ronoxan, an antioxidant) to have an improvement in antioxidant capability compared to each of the individual components alone. However, the benefit provided by the levels of phospholipids taught by the present invention greatly exceed the benefit provided by Ronoxan. Significantly, the benefits of adding concentrations of phospholipids higher than 2000 ppm, could not be predicted from the benefits of adding phospholipids at 2000 ppm or less.
That the present inventors' discovery is unexpected is further accentuated by the observation that in Ronoxan the combination of ascorbyl palmitate and tocopherol is required in conjunction with phospholipids in order to provide antioxidant capability. The methods and products of the present invention have no such requirement. As shown in Example 2, which compares induction times for DHASCO® plus 250 ppm ascorbyl palmitate and 250 ppm mixed tocopherols supplemented with the phospholipids of the present invention vs. DHASCO® supplemented only with the phospholipids of the present invention, a given amount of phospholipids is effective to substantially increase the stability of the oil for DHASCO® without additional antioxidants as well as for DHASCO® with additional antioxidants. The present invention provides for the addition of vegetable-derived, milk- derived, and/or microbial-derived phospholipids to the fat blend or food fat of infant formulas and other food products at levels up to 30% by weight of the fat blend, formula fat, or other food fat. Preferably, the phospholipids are added at levels of from 0.4% to 20% (preferably 0.5% to 20%, more preferably 1% to 16%, and even more preferably 4% to 16%) of the fat blend. Preferably the phospholipids are added in an amount effective to substantially increase the stability, particularly the oxidative stability, of the fat blend. An amount effective to substantially increase the stability is an amount effective to increase the induction time by 50% above the induction time of the same fat blend to which the phospholipids of this invention have not been added. Preferably, the effective amount of phospholipids will increase the induction time by a factor of 2 to 5 times greater than the induction time of the same fat blend to which the phospholipids of this invention have not been added.
Typically, greater increases in induction time are preferable. However, it is understood that increasing the amount of phospholipids added to a fat blend above a certain amount may not be desirable in certain contexts or conditions. Therefore, it is understood that a balance may be found wherein the stability of the fat blend is substantially increased, but phospholipids are not added to an undesirable level.
The amount of the phospholipids of the present invention which will constitute an effective amount may vary with the components of the fat blend the stability of which is desired to be increased. The optimal amount of phospholipids to add to a particular fat blend may be determined through routine optimization studies. As an example, Example 1 presents an experiment wherein the stabilizing effect of the phospholipids of the present invention on a blend of DHASCO® and ARASCO® is examined. In contrast, Example 2 an experiment wherein the stabilizing effect of the phospholipids of the present invention on DHASCO® is examined. It can be seen from the results that optimum amounts of phospholipids vary slightly between the blend versus the DHASCO® alone.
The phospholipids of this invention may be added in addition to other stabilizing agents such as, but not limited to, tocopherols, ascorbic acid and its derivatives, such as ascorbyl palmitate, and BHT. Such stabilizing agents will be referred to as "additional stabilizing agents" or "additional antioxidants." The high levels of phospholipids conceived in this invention provide unexpected chemical (e.g., oxidative) stability to the fat blend used in the formula or food by generating an emulsion which is beneficial to the spray drying process. The levels of phospholipids added according to the present invention are much higher than the upper limits previously though to be useful, and it is an unexpected result that the increasing levels of phospholipid addition provide increasing levels of stability. Further, the phospholipids of the present invention provide their stabilizing effect in the absence of any other antioxidants or stabilizers. However, such other antioxidants and/or stabilizers may optionally be added to oil blends in combination with the phospholipids of the present invention.
Furthermore, the addition of phospholipids should impart an additional nutritive benefit to the infant formula as these components are important in the metabolism and physiology of the growing infant. Furthermore, the addition of the phospholipids have imparted a previously unexpected stability on certain oils which are rich in ARA and /or DHA, such as, but not limited to, ARA-containing oil from Mortierella alpina (see U.S. Patent No. 5,658,767 to Kyle), DHA-containing oil from Crypthecodinium cohnii (see U.S. Patent No. 5,492,938 to Kyle et al.; U.S. Patent No. 5,407,957 to Kyle, et al.; U.S. Patent No. 5,397,591 to Kyle et al.), and DHA-containing oil from Thraustochytrium species (see U.S. Patent No. 5,130,242 to Barclay).
Preparation of the source HUFA-containing oils and manufacture of HUFA- containing foods and nutritional supplements, including infant formula and baby food, are described in more detail in the various patents and patent applications cited herein, which are all incorporated herein by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference.
Example 1.
The antioxidant effectiveness of lecithin in a blend of DHASCO® (a DHA- rich oil from Crypthecodinium cohnii) and ARASCO® (an ARA-rich triglyceride oil from Mortierella alpina) was investigated. DHASCO® and ARASCO® each are supplemented with 250 ppm ascorbyl palmitate and 250 ppm mixed tocopherols.
Lots of Formulaid (an oil containing ARASCO® and DHASCO®) were blended to yield an oil containing DHA and ARA in a ratio of 1:1.5. Specifically, lots F01723-DS-7 (DHA: ARA of 1:1) and F01723-DS-1 (DHA: ARA of 1:2) were blended in a 1 : 1 ratio.
Bleached lecithin (Yelkin TS from ADM, lot #PG386) was added to the oil blend. The lecithin contained approximately 63% phospholipids (as acetone insoluble matter) and soybean oil. ADM states that the lecithin naturally contains approximately 1000 ppm tocopherol, but no added antioxidants. The lecithin was added to the oil blend at concentrations of 0.4%, 0.8%, 4.0%, and 8.0% and mixed well. Induction time was analyzed on a Rancimat using standard settings (20 mL/minute, 90°C) according to the Official Method set forth by the American Oil Chemists' Society (AOCS) (see, Official Methods and Recommended Practice of the AOCS, 5th ed., Cdl2.b-92, "Oil Stability Index"). Oxidative stability may also be assessed using the active oxygen method (AOM), which is well-known in the art.
Addition of lecithin extended the induction time in a dose-dependent manner. Surprisingly, for every one percent Yelkin added, the induction time was increased by approximately seven to eight hours. Expressed in phospholipids, for every one percent of phospholipid added, the induction time was increased by approximately ten to twelve hours. These effects are much greater than can be explained by any effects of dilution of the oil blend. Table 1 presents the results in tabular form; Figure 1 presents results in graphic from.
Example 2.
The antioxidant effectiveness of lecithin in DHASCO® (a DHA-rich oil from Crypthecodinium cohnii) supplemented with 250 ppm ascorbyl palmitate and 250 ppm mixed tocopherols was investigated and compared to the antioxidant effectiveness of lecithin in DHASCO® with neither ascorbyl palmitate nor tocopherols added ("DHASCO® w/o antioxidant").
Bleached lecithin (Yelkin TS from ADM, lot #PG386) was added to the DHASCO®. The lecithin contained approximately 63% phospholipids (as acetone insoluble matter) and soybean oil. ADM states that the lecithin naturally contains approximately 1000 ppm tocopherol, but no added antioxidants. The lecithin was added to the DHASCO® at concentrations of 1.0%, 2.0%, 4.0%, and 8.0% or 16.0% and mixed well. Induction time was analyzed on a Rancimat using standard settings (20 mL/minute, 90°C) according to the Official Method set forth by the American Oil Chemists' Society (AOCS) (see, Official Methods and Recommended Practice of the AOCS, 5th ed., Cdl2.b-92, "Oil Stability Index"). Oxidative stability may also be assessed using the active oxygen method (AOM), which is well-known in the art.
Addition of lecithin extended the induction time in a dose-dependent manner. Surprisingly, for every one percent Yelkin added, the induction time was increased by approximately four to five hours. Expressed in phospholipids, for every one percent of phospholipid added, the induction time was increased by approximately seven to eight hours. These effects are much greater than can be explained by any effects of dilution of the oil. Table 2 presents the results in tabular form; Figure 2 presents results in graphic from.
For purposes of clarity of understanding, the foregoing invention has been described in some detail by way of illustrations and examples in conjunction with specific embodiments, although other aspects, advantages and modifications will be apparent to those skilled in the art to which the invention pertains. The foregoing description and examples are intended to illustrate, but not limit the scope of the invention. Modifications of the above-described modes for carrying out the invention that are apparent to persons of skill in food science, agricultural engineering, edible oil processing, and/or related fields are intended to be within the scope of the invention, which is limited only by the appended claims. All publications and patent applications mentioned in this specification are indicative of the level of skill of those skilled in the art to which this invention pertains. Table 1
Figure imgf000013_0001
Table 2
Figure imgf000013_0002

Claims

CLAIMS:
1. A food product containing mixed glycerides, wherein the mixed glycerides comprise polyunsaturated fatty acid residues, highly unsaturated fatty acid residues, or a combination thereof, and further wherein the polyunsaturated fatty acid residues, highly unsaturated fatty acid residues, or combination thereof is stabilized by the addition of phospholipids.
2. The food product according to claim 1, further wherein the phospholipids are derived from non-animal sources.
3. The food product according to claim 1 wherein the phospholipids are derived from vegetable, milk, or microbial sources, or a combination thereof.
4. The food product according to claim 1, further wherein the phospholipids are derived from byproducts of the process of refining vegetable oil.
5. The food product according to claim 1, further wherein the phospholipids are derived from milk processing waste products.
6. The food product according to claim 1, further wherein the phospholipids are derived from yeast brewing waste products.
7. The food product of claim 1, further wherein the food product is an infant formula or baby food.
8. The food product of claim 1, further wherein the food product is a nutritional supplement.
9. The food product of claim 1 further comprising additional antioxidants.
10. The food product of claim 1, wherein additional antioxidants are not added to the food product.
11. A method of preparing a food product containing mixed glycerides, wherein the mixed glycerides comprise polyunsaturated fatty acid residues, highly unsaturated fatty acid residues, or a combination thereof, comprising blending phospholipids with the mixed glycerides such that the polyunsaturated fatty acid residues, highly unsaturated fatty acid residues, or combination thereof is stabilized by the addition of the phospholipids.
12. The method according to claim 11, further wherein the phospholipids are derived from non-animal sources.
13. The method according to claim 11 wherein the phospholipids are derived from vegetable, milk, or microbial sources, or a combination thereof.
14. The method according to claim 11, further wherein the phospholipids are derived from byproducts of the process of refining vegetable oil.
15. The method according to claim 11, further wherein the phospholipids are derived from milk processing waste products.
16. The method according to claim 11, further wherein the phospholipids are derived from yeast brewing waste products.
17. The method of claim 11 , further wherein the food product is an infant formula or baby food.
18. The method of claim 11, further wherein the food product is a nutritional supplement.
19. The method of claim 11 further comprising adding additional antioxidants to the food product.
20. The method of claim 11, wherein additional antioxidants are not added to the food product.
PCT/US2000/006755 1999-03-16 2000-03-16 Infant formulas and other food products containing phospholipids WO2000054575A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU38845/00A AU3884500A (en) 1999-03-16 2000-03-16 Infant formulas and other food products containing phospholipids

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US12450399P 1999-03-16 1999-03-16
US60/124,503 1999-03-16
US17601900P 2000-01-14 2000-01-14
US60/176,019 2000-01-14

Publications (2)

Publication Number Publication Date
WO2000054575A2 true WO2000054575A2 (en) 2000-09-21
WO2000054575A3 WO2000054575A3 (en) 2000-12-28

Family

ID=26822675

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/006755 WO2000054575A2 (en) 1999-03-16 2000-03-16 Infant formulas and other food products containing phospholipids

Country Status (2)

Country Link
AU (1) AU3884500A (en)
WO (1) WO2000054575A2 (en)

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6977166B1 (en) 1999-07-14 2005-12-20 The University Of Hull Method of producing an oil including docosahexaenoic acid
WO2006079533A2 (en) * 2005-01-26 2006-08-03 Nutrinova Nutrition Specialties & Food Ingredients Gmbh Production and use of an antioxidant extract from crypthecodinium sp.
WO2007102913A2 (en) * 2005-12-16 2007-09-13 Solae, Llc Phospholipid-stabilized oxidizable material
WO2007102915A2 (en) * 2005-12-16 2007-09-13 Solae, Llc Encapsulated phospholipid-stabilized oxidizable material
WO2009095435A1 (en) * 2008-01-30 2009-08-06 Bnlfood Investments Sarl Lecithin based composition and its use in food
EP1710296A4 (en) * 2003-12-02 2009-11-25 Suntory Holdings Ltd Fat composition containing phospholipid and long-chain polyunsaturated fatty acid-supplying compound and food using the same
US7674609B2 (en) 2001-02-09 2010-03-09 The University Of Hull Culture of Crypthecodinium cohnii and microorganisms derived therefrom
US20100086638A1 (en) * 2006-04-03 2010-04-08 Kyle David J Feed formulations containing docosahexaenoic acid
US9023616B2 (en) 2006-08-01 2015-05-05 Dsm Nutritional Products Ag Oil producing microbes and method of modification thereof
WO2016034517A1 (en) * 2014-09-02 2016-03-10 Loders Croklaan B.V. Composition
EP1814399B1 (en) 2004-10-12 2016-05-18 Fonterra Co-Operative Group Limited Beta-serum dairy products, neutral lipid-depleted and/or polar lipid-enriched dairy products, and processes for their production
US9719116B2 (en) 2005-06-07 2017-08-01 Dsm Nutritional Prodcuts Ag Eukaryotic microorganisms for producing lipids and antioxidants
US9873880B2 (en) 2013-03-13 2018-01-23 Dsm Nutritional Products Ag Engineering microorganisms
US9951326B2 (en) 2015-07-13 2018-04-24 MARA Renewables Corporation Enhancing microbial metabolism of C5 organic carbon
US10385370B2 (en) 2016-06-10 2019-08-20 MARA Renewables Corporation Method of making lipids with improved cold flow properties
WO2020214685A1 (en) * 2019-04-16 2020-10-22 Locus Ip Company, Llc Microbe-based emulsifying food additives
WO2022036051A1 (en) * 2020-08-12 2022-02-17 Locus Ip Company, Llc Natural skincare compositions
US11578304B2 (en) 2015-03-26 2023-02-14 MARA Renewables Corporation High density production of biomass and oil using crude glycerol
EP3972417A4 (en) * 2019-05-20 2023-05-10 AAK AB (publ) Increasing stability of lc-pufa
US11666074B2 (en) 2017-12-26 2023-06-06 Locus Solutions Ipco, Llc Organic food preservative compositions

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4315955A (en) * 1980-03-10 1982-02-16 Madison Creamery, Inc. Filled cream, butter-like product made therefrom and method of manufacturing them
US5023271A (en) * 1985-08-13 1991-06-11 California Biotechnology Inc. Pharmaceutical microemulsions
US5709888A (en) * 1990-10-30 1998-01-20 Abbott Laboratories High fat nutritional formula for infants and adults
US6036992A (en) * 1997-03-28 2000-03-14 Abbott Laboratories Process of making an enteral formula containing long-chain polyunsaturated fatty acids

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4315955A (en) * 1980-03-10 1982-02-16 Madison Creamery, Inc. Filled cream, butter-like product made therefrom and method of manufacturing them
US5023271A (en) * 1985-08-13 1991-06-11 California Biotechnology Inc. Pharmaceutical microemulsions
US5709888A (en) * 1990-10-30 1998-01-20 Abbott Laboratories High fat nutritional formula for infants and adults
US6036992A (en) * 1997-03-28 2000-03-14 Abbott Laboratories Process of making an enteral formula containing long-chain polyunsaturated fatty acids

Cited By (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6977166B1 (en) 1999-07-14 2005-12-20 The University Of Hull Method of producing an oil including docosahexaenoic acid
US7674609B2 (en) 2001-02-09 2010-03-09 The University Of Hull Culture of Crypthecodinium cohnii and microorganisms derived therefrom
EP1710296A4 (en) * 2003-12-02 2009-11-25 Suntory Holdings Ltd Fat composition containing phospholipid and long-chain polyunsaturated fatty acid-supplying compound and food using the same
EP1814399B1 (en) 2004-10-12 2016-05-18 Fonterra Co-Operative Group Limited Beta-serum dairy products, neutral lipid-depleted and/or polar lipid-enriched dairy products, and processes for their production
WO2006079533A2 (en) * 2005-01-26 2006-08-03 Nutrinova Nutrition Specialties & Food Ingredients Gmbh Production and use of an antioxidant extract from crypthecodinium sp.
WO2006079533A3 (en) * 2005-01-26 2006-11-16 Nutrinova Gmbh Production and use of an antioxidant extract from crypthecodinium sp.
JP2008528742A (en) * 2005-01-26 2008-07-31 ヌートリノーヴァ ニュートリション スペシャルティーズ アンド フード イングリーディエンツ ゲーエムベーハー Production and use of antioxidant extracts from Crypthecodinium
AU2006208644B2 (en) * 2005-01-26 2010-07-08 Nutrinova Nutrition Specialties & Food Ingredients Gmbh Production and use of an antioxidant extract from Crypthecodinium sp.
KR100918891B1 (en) * 2005-01-26 2009-09-23 뉴트리노바 뉴트리션 스페셜티 앤드 푸드 인그레디엔츠 게엠베하 Production and use of an antioxidant extract from Crypthecodinium sp.
US10435725B2 (en) 2005-06-07 2019-10-08 Dsm Nutritional Products Ag Eukaryotic microorganisms for producing lipids and antioxidants
US9719116B2 (en) 2005-06-07 2017-08-01 Dsm Nutritional Prodcuts Ag Eukaryotic microorganisms for producing lipids and antioxidants
WO2007102913A3 (en) * 2005-12-16 2007-11-15 Solae Llc Phospholipid-stabilized oxidizable material
WO2007102915A3 (en) * 2005-12-16 2007-11-15 Solae Llc Encapsulated phospholipid-stabilized oxidizable material
WO2007102915A2 (en) * 2005-12-16 2007-09-13 Solae, Llc Encapsulated phospholipid-stabilized oxidizable material
WO2007102913A2 (en) * 2005-12-16 2007-09-13 Solae, Llc Phospholipid-stabilized oxidizable material
US20100086638A1 (en) * 2006-04-03 2010-04-08 Kyle David J Feed formulations containing docosahexaenoic acid
US9023616B2 (en) 2006-08-01 2015-05-05 Dsm Nutritional Products Ag Oil producing microbes and method of modification thereof
EP2100897A1 (en) * 2008-01-30 2009-09-16 BNLfood Investments SARL Lecithin based composition and its use in food
WO2009095435A1 (en) * 2008-01-30 2009-08-06 Bnlfood Investments Sarl Lecithin based composition and its use in food
US9873880B2 (en) 2013-03-13 2018-01-23 Dsm Nutritional Products Ag Engineering microorganisms
WO2016034517A1 (en) * 2014-09-02 2016-03-10 Loders Croklaan B.V. Composition
CN106714566A (en) * 2014-09-02 2017-05-24 荷兰洛德斯克罗科兰有限公司 Composition
JP2017525396A (en) * 2014-09-02 2017-09-07 ロダース クロクラーン ビー.ブイ. Composition
KR20170047329A (en) * 2014-09-02 2017-05-04 로더스 크로크란 비.브이. Composition
KR102548822B1 (en) 2014-09-02 2023-06-29 번지 로더스 크로크란 비.브이. Composition
US11578304B2 (en) 2015-03-26 2023-02-14 MARA Renewables Corporation High density production of biomass and oil using crude glycerol
US9951326B2 (en) 2015-07-13 2018-04-24 MARA Renewables Corporation Enhancing microbial metabolism of C5 organic carbon
US10662418B2 (en) 2015-07-13 2020-05-26 MARA Renewables Corporation Enhancing microbial metabolism of C5 organic carbon
US10385370B2 (en) 2016-06-10 2019-08-20 MARA Renewables Corporation Method of making lipids with improved cold flow properties
US10851395B2 (en) 2016-06-10 2020-12-01 MARA Renewables Corporation Method of making lipids with improved cold flow properties
US11959120B2 (en) 2016-06-10 2024-04-16 MARA Renewables Corporation Method of making lipids with improved cold flow properties
US11666074B2 (en) 2017-12-26 2023-06-06 Locus Solutions Ipco, Llc Organic food preservative compositions
WO2020214685A1 (en) * 2019-04-16 2020-10-22 Locus Ip Company, Llc Microbe-based emulsifying food additives
EP3972417A4 (en) * 2019-05-20 2023-05-10 AAK AB (publ) Increasing stability of lc-pufa
WO2022036051A1 (en) * 2020-08-12 2022-02-17 Locus Ip Company, Llc Natural skincare compositions

Also Published As

Publication number Publication date
AU3884500A (en) 2000-10-04
WO2000054575A3 (en) 2000-12-28

Similar Documents

Publication Publication Date Title
WO2000054575A2 (en) Infant formulas and other food products containing phospholipids
Michalski et al. Multiscale structures of lipids in foods as parameters affecting fatty acid bioavailability and lipid metabolism
CA2451116C (en) Production and use of a polar lipid-rich fraction containing omega-3 and/or omega-6 highly unsaturated fatty acids from microbes, genetically modified plant seeds and marine organisms
Imoisi et al. Palm oil, its nutritional and health implications
Martin et al. Oxidative stability of structured lipids
AU2007238131B2 (en) Food products comprising long chain polyunsaturated fatty acids and methods for preparing the same
CA2316298C (en) Fat blend
US20090324636A1 (en) Fish oil in stabilized form
US20040209953A1 (en) Glyceride compositions and methods of making and using same
Sardesai The essential fatty acids
Sim Designer eggs and their nutritional and functional significance
JP2010535526A (en) Lecithin and LC-PUFA
Uauy-Dagach et al. Marine oils: the health benefits of n-3 fatty acids
BRPI0714732A2 (en) Use of DPA (n-6) Oils in Infant Formula
WO2009105620A1 (en) Selective short chain monounsaturated oils
US20070104856A1 (en) Fish oils with an altered fatty acid profile, method of producing same and their use
Li et al. New human milk fat substitutes from butterfat to improve fat absorption
MX2008011351A (en) Stearidonic acid for improving cardiovascular health.
Al-Khalifa Production of added-value poultry meat: enrichment with n-3 polyunsaturated fatty acids
Pak Stability and quality of fish oil during typical domestic application
Przybylski et al. Oil composition and properties
Mekonnen et al. Effect of locally manufactured niger seed oil on lipid profile compared to imported palm and sunflower oils on rat models
Begum et al. Fatty acid composition of hilsa (Tenualosa ilisha) fish muscle from different locations in Bangladesh.
Molla et al. Nutritional status, characterization and fatty acid composition of oil and lecithin isolated from fresh water fish shoul (Channa striata)
Shahidi et al. Marine lipids as affected by processing and their quality preservation by natural antioxidants

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase